Stock Events

Stock Events

Xenon Pharmaceuticals 

$60.00
35
-$2.32-3.72% 17:09 Today

Statistics

Day High
62.51
Day Low
59.72
52W High
72.66
52W Low
35.6
Volume
212,643
Avg. Volume
1,331,961
Mkt Cap
5.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.18
-1.06
-0.95
-0.83
Expected EPS
-1.135403
Actual EPS
N/A

Financials

-4,612.13%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.5MRevenue
-345.91MNet Income

Analyst Ratings

77.00Average Price Target
The highest estimate is 97.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XENE. It's not an investment recommendation.
Apple
8
AAPL
Microsoft
7
MSFT
Broadcom
7
AVGO
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Xenon's focus on neurological disorders.
Biogen
BIIB
Mkt Cap31B
Biogen competes in the neurological disorder space, particularly in developing therapies for diseases like multiple sclerosis and Alzheimer's, overlapping with Xenon's target market.
Alkermes
ALKS
Mkt Cap8.23B
Alkermes competes with Xenon in developing treatments for central nervous system (CNS) disorders, including schizophrenia and bipolar disorder.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals is a competitor due to its focus on RNA-targeted drug discovery for neurological diseases, a similar area of interest as Xenon.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
ACADIA Pharmaceuticals targets the CNS disorder market, with a focus on psychosis and schizophrenia treatments, areas that overlap with Xenon's research interests.
AMGEN
AMGN
Mkt Cap224.63B
Amgen, with its broad focus on biotechnological therapies for various conditions, competes indirectly with Xenon through its investments in neuroscience and neurodegenerative diseases.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics operates in the space of rare diseases, including neurological disorders, making it a competitor to Xenon's specialized focus.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat genetic disorders, competing with Xenon's approach to drug development.

About

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Show more...
CEO
Ian C. Mortimer
Employees
370
Country
Canada
ISIN
CA98420N1050
WKN
000A12ETN

Listings

STU
DE
XP0.STU
XNAS
US
XENE
F
DE
XP0.F
MU
DE
XP0.MU

0 Comments

Share your thoughts

FAQ

What is Xenon Pharmaceuticals stock price today?▼
The current price of XENE is $60.00 USD — it has decreased by -3.72% in the past 24 hours. Watch Xenon Pharmaceuticals stock price performance more closely on the chart.
What is Xenon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Xenon Pharmaceuticals stocks are traded under the ticker XENE.
Is Xenon Pharmaceuticals stock price growing?▼
XENE stock has fallen by -6.38% compared to the previous week, the month change is a -8.95% fall, over the last year Xenon Pharmaceuticals has showed a +59.75% increase.
What is Xenon Pharmaceuticals market cap?▼
Today Xenon Pharmaceuticals has the market capitalization of 5.8B
When is the next Xenon Pharmaceuticals earnings date?▼
Xenon Pharmaceuticals is going to release the next earnings report on November 11, 2026.
What were Xenon Pharmaceuticals earnings last quarter?▼
XENE earnings for the last quarter are -1.11 USD per share, whereas the estimation was -1.14 USD resulting in a +2.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xenon Pharmaceuticals revenue for the last year?▼
Xenon Pharmaceuticals revenue for the last year amounts to 7.5M USD.
What is Xenon Pharmaceuticals net income for the last year?▼
XENE net income for the last year is -345.91M USD.
How many employees does Xenon Pharmaceuticals have?▼
As of August 20, 2026, the company has 370 employees.
In which sector is Xenon Pharmaceuticals located?▼
Xenon Pharmaceuticals operates in the Health & Wellness sector.
When did Xenon Pharmaceuticals complete a stock split?▼
Xenon Pharmaceuticals has not had any recent stock splits.
Where is Xenon Pharmaceuticals headquartered?▼
Xenon Pharmaceuticals is headquartered in BURNABY, Canada.